沃森生物(300142.SZ):雙價HPV疫苗已完成全國主要省份的准入,處於逐步放量、市場下沉階段
格隆匯5月12日丨有投資者在投資者互動平台向沃森生物(300142.SZ)提問,“二價HPV疫苗詢單情況如何? 是不是需求端突然冷卻了?”
沃森生物回覆稱,今年是公司雙價 HPV 疫苗上市後的第一個完整銷售年,目前雙價HPV疫苗已完成全國主要省份的准入,處於逐步放量、市場下沉階段。公司將強化對國內各級市場的滲透,並大力拓展海外市場。具體銷售情況請以後續定期報吿披露信息為準。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.